Impact of the Pathologist on Prostate Biopsy Diagnosis and Immunohistochemical Stain Usage Within a Single Institution

Am J Clin Pathol. 2017 Nov 20;148(6):494-501. doi: 10.1093/ajcp/aqx103.

Abstract

Objectives: To determine whether pathologists in a tertiary care institution vary in diagnosis and immunohistochemical stain usage in prostate biopsy specimens.

Methods: Men who underwent prostate needle biopsies between 2008 and 2013 were included.

Results: In total, 1,777 prostate biopsy specimens diagnosed by nine pathologists showed variation in diagnostic reporting (atypical small acinar proliferation, 2.0%-8.0%; high-grade prostatic intraepithelial neoplasia, 2.0%-8.5%; nonneoplastic, 30.2%-48.3%; adenocarcinoma, 46.2%-55.3%; P < .001). Variation in Gleason scoring was observed (P < .001), with the 4 + 3 = 7 category having the greatest variability (6.9%-30.3%). A blinded review from the most outlying pathologist in this category revealed 45% grading discrepancies. The mean number of immunostains performed per case (0.3-1.2) differed between pathologists (P < .001), and one pathologist used immunostains at twice the rate of the remaining cohort.

Conclusions: Case pathologist significantly affects prostate biopsy diagnosis and immunohistochemical workup. We recommend evaluation for outlying practice patterns to provide consistent and efficient patient care.

Keywords: IHC; Needle biopsy; Pathologist; Practice patterns; Prostate.

MeSH terms

  • Adenocarcinoma / diagnosis
  • Adenocarcinoma / pathology
  • Adult
  • Aged
  • Biomarkers, Tumor / analysis
  • Biopsy, Needle / methods
  • Humans
  • Immunohistochemistry / methods
  • Male
  • Middle Aged
  • Neoplasm Grading / methods
  • Prostate / pathology*
  • Prostatic Intraepithelial Neoplasia / diagnosis
  • Prostatic Intraepithelial Neoplasia / pathology*
  • Prostatic Neoplasms / diagnosis
  • Prostatic Neoplasms / pathology*

Substances

  • Biomarkers, Tumor